Fibrillary glomerulonephritis (FGN) remains one of the least-studied glomerular diseases in nephrology, accounting for less than 1% of kidney biopsies and offering clinicians few evidence-based treatment options.

Andrew Bomback, MD, MPH, opens the segment by asking Gerald Appel, MD, how he defines a non-responder in fibrillary glomerulonephritis (FGN) in practice, how long patients should remain on therapy, and what numbers signal that treatment is not working.

Discover how Columbia experts rule out secondary causes and weigh the evidence for rituximab when fibrillary glomerulonephritis fails first-line therapy.

Explore when Columbia experts escalate to immunosuppression in fibrillary glomerulonephritis and how biopsy pattern shapes their choice of regimen.

Discover the four-drug conservative regimen one Columbia nephrologist uses to slow fibrillary glomerulonephritis progression without immunosuppression.

Understand how nonspecific therapy lowers cardiovascular risk in fibrillary glomerulonephritis and why transplant recurrence may be lower than reported.

Explore how proteinuria targets and treatment decisions for non-responders differ across IgA nephropathy, lupus nephritis, and membranous nephropathy.

Discover which therapeutic targets and multicenter trial designs Columbia experts see as the next step for fibrillary glomerulonephritis research.